Transgene reports mixed results from Phase II trial of cancer vaccine TG4001 in HPV16-positive cancers
Summary: Transgene announced that its Phase II trial of the cancer vaccine TG4001, combined with avelumab, did not improve progression-free survival in patients with recurrent or metastatic HPV16-positive cervical and anogenital cancers.
However, a subgroup analysis indicated a positive trend for the TG4001 regimen in cervical cancer patients, who make up about half of the study participants. The treatment was well tolerated, with adverse events consistent with previous findings.
Transgene will conduct a full analysis of the trial data before determining the next steps for TG4001. A conference call is scheduled for today to discuss the results further.
This is article metrics. Combined, they form a significance score, that indicates how important the news is on a scale from 0 to 10.
My algorithm scores 10,000 news articles daily, and creates a single significance-ordered list of news.
Read more about how I calculate significance, or see today's top ranked news on the main page:
See today's news rankings